Table 1.
Baseline characteristics of participants in the standard therapy arm of the glycaemia trial who achieved glycated haemoglobin <8.0 or ≥8.0% by 12 months.
| Demographics | HbA1c <8.0% | HbA1c ≥8.0% | p* |
|---|---|---|---|
| No. of participants, % | 3194 (68.18) | 1491 (31.82) | |
| Mean (s.d.) age, years | 62.72 (6.75) | 61.25 (6.74) | <0.001 |
| Mean (s.d.) BMI, kg/m2 | 32.11 (5.38) | 32.50 (5.58) | 0.020 |
| Mean (s.d.) duration of diabetes, years | 10.43 (7.62) | 12.05 (7.88) | <0.001 |
| Mean (s.d.) baseline HbA1c, % | 8.13 (0.97) | 8.66 (1.10) | <0.001 |
| Female, n (%) | 1170 (36.6) | 592 (39.7) | 0.043 |
| Race, n (%) | |||
| Hispanic | 241 (6.7) | 132 (8.9) | <0.001 |
| Black | 494 (15.5) | 326 (21.9) | |
| White | 2129 (66.7) | 859 (57.6) | |
| Other | 357 (11.2) | 174 (11.7) | |
| History of cardiovascular disease event, n (%) | 1058 (33.1) | 561 (37.6) | 0.003 |
| Managed by endocrinologist/diabetologist investigator, n (%) | 1848 (57.9) | 855 (57.3) | 0.740 |
| Metformin use at baseline, n (%) | 1913 (60.0) | 870 (58.6) | 0.338 |
| Secretagogues use at baseline | 1017 (31.91%) | 467 (31.43%) | 0.741 |
| Thiazolidinediones use at baseline | 624 (19.58%) | 275 (18.51%) | 0.386 |
| Bolus insulin use at baseline | 373 (11.70%) | 277 (18.64%) | <0.001 |
| Premixed insulin use at baseline | 275 (8.63%) | 167 (11.24%) | 0.005 |
| Basal insulin use at baseline | 739 (23.19%) | 533 (35.87%) | <0.001 |
| Number of oral medication classes used at baseline | 1.12 (0.88) | 1.09 (0.86) | 0.288 |
BMI, bodymass index; HbA1c, glycated haemoglobin; s.d., standard deviation.
*
p values were calculated using chi-squared tests for categorical variables and two-sample t-tests for continuous variables.